-
公开(公告)号：US20170320839A1
公开(公告)日：2017-11-09
申请号：US15406128
申请日：2017-01-13
Applicant: Celgene International II Sàrl
Inventor： Esther Martinborough , Marcus F. Boehm , Adam Richard Yeager , Junko Tamiya , Liming Huang , Enugurthi Brahmachary , Manisha Moorjani , Gregg Alan Timony , Jennifer L. Brooks , Robert Peach , Fiona Lorraine Scott , Michael Allen Hanson
IPC: C07D271/06 , C07D413/14 , C07D413/12 , C07D413/10 , C07C311/13 , C07C245/14 , A61K31/4245 , A61K45/06 , A61K31/5377 , A61K31/496 , A61K31/454 , A61K31/427 , C07D417/12 , C07C255/58
CPC classification number: C07D271/06 , A61K31/4245 , A61K31/427 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K45/06 , C07C245/14 , C07C255/58 , C07C311/13 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12
Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.
-
公开(公告)号：US10239846B2
公开(公告)日：2019-03-26
申请号：US15406128
申请日：2017-01-13
Applicant: Celgene International II Sàrl
Inventor： Esther Martinborough , Marcus F. Boehm , Adam Richard Yeager , Junko Tamiya , Liming Huang , Enugurthi Brahmachary , Manisha Moorjani , Gregg Alan Timony , Jennifer L. Brooks , Robert Peach , Fiona Lorraine Scott , Michael Allen Hanson
IPC: A61K31/4245 , A61K45/06 , A61K31/5377 , A61K31/496 , A61K31/454 , A61K31/427 , C07D271/06 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07C245/14 , C07C255/58 , C07C311/13
Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.
-
公开(公告)号：US09700543B2
公开(公告)日：2017-07-11
申请号：US14997364
申请日：2016-01-15
Applicant: Celgene International II SÀRL
Inventor： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Thomas Fowler , Andrew Novak , Premji Meghani , Enugurthi Brahmachary , Adam Richard Yeager
IPC: A61K31/4245 , A61K9/00 , A61K47/20 , A61K47/26 , A61K47/40 , A61K47/48 , A61K45/06 , A61K31/155 , A61K38/26 , C07C255/57 , C07D213/79 , C07D213/80 , C07D213/81 , C07D213/82 , C07D309/06 , C07D309/08 , C07D311/16 , C07C271/28 , C07D215/48 , C07D217/02 , C07C275/42 , C07D317/68 , C07D231/12 , C07D333/38 , C07D233/60 , C07C311/08 , C07C311/13 , C07C311/21 , C07D235/06 , C07C311/29 , C07D235/12 , C07D235/18 , C07C311/48 , C07D239/26 , C07D239/28 , C07C317/28 , C07C317/44 , C07D239/74 , C07D413/04 , C07D239/91 , C07D413/12 , C07D241/42 , C07D241/44 , C07D417/12 , C07C323/62 , C07C229/14 , C07D249/08 , C07D257/04 , C07C233/47 , C07C233/51 , C07D261/18 , C07C233/81 , C07C233/83 , C07C235/12 , C07D263/32 , C07C235/38 , C07D263/34 , C07C235/48 , C07D263/48 , C07D263/57 , C07C237/22 , C07C237/36 , C07C237/42 , C07D271/06 , C07D271/07 , C07D271/107 , C07D207/267 , C07D277/30 , C07D209/08 , C07D277/56 , C07D277/66 , C07D279/12 , C07D211/14 , C07D211/34 , C07D211/62 , C07D295/15 , C07D295/155 , C07D295/205 , C07D213/55 , C07D213/65 , C07D307/24 , C07D307/54 , C07D307/68 , C07D307/79 , C08B37/16 , C08L5/16 , B82Y5/00 , A61K31/235 , A61K31/341 , A61K31/4406 , A61K31/4465 , A61K31/495 , A61K31/505 , A61K31/5375 , A61K31/54 , C07D295/24 , A61K31/4439 , A61K31/4725
CPC classification number: A61K31/4245 , A61K9/0019 , A61K9/0095 , A61K31/155 , A61K31/235 , A61K31/341 , A61K31/4406 , A61K31/4439 , A61K31/4465 , A61K31/4725 , A61K31/495 , A61K31/505 , A61K31/5375 , A61K31/54 , A61K38/22 , A61K38/26 , A61K45/06 , A61K47/20 , A61K47/26 , A61K47/40 , A61K47/6951 , B82Y5/00 , C07C229/14 , C07C233/47 , C07C233/51 , C07C233/81 , C07C233/83 , C07C235/12 , C07C235/38 , C07C235/48 , C07C237/22 , C07C237/36 , C07C237/42 , C07C255/57 , C07C271/28 , C07C275/42 , C07C311/08 , C07C311/13 , C07C311/21 , C07C311/29 , C07C311/48 , C07C317/28 , C07C317/44 , C07C323/62 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D207/267 , C07D209/08 , C07D211/14 , C07D211/34 , C07D211/62 , C07D213/55 , C07D213/65 , C07D213/79 , C07D213/80 , C07D213/81 , C07D213/82 , C07D215/48 , C07D217/02 , C07D231/12 , C07D233/60 , C07D235/06 , C07D235/12 , C07D235/18 , C07D239/26 , C07D239/28 , C07D239/74 , C07D239/91 , C07D241/42 , C07D241/44 , C07D249/08 , C07D257/04 , C07D261/18 , C07D263/32 , C07D263/34 , C07D263/48 , C07D263/57 , C07D271/06 , C07D271/07 , C07D271/107 , C07D277/30 , C07D277/56 , C07D277/66 , C07D279/12 , C07D295/15 , C07D295/155 , C07D295/205 , C07D295/24 , C07D307/24 , C07D307/54 , C07D307/68 , C07D307/79 , C07D309/06 , C07D309/08 , C07D311/16 , C07D317/68 , C07D333/38 , C07D413/04 , C07D413/12 , C07D417/12 , C08B37/0015 , C08L5/16 , A61K2300/00
Abstract: Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP(1-42), PTH(1-34), Glucagon(1-29), GLP-2(1-33), GLP-1(7-36), GLP-1(9-36), oxyntomodulin and exendin variants.
-
-
Search Results
3
records
(took 0.016 seconds)
